



Pioneering science delivers vital medicines™



About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing novel medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Reaching Patients Worldwide

Amgen medicines help patients around the world. The company has facilities or subsidiaries in the following locations:

United States (including Puerto Rico)

California (Fremont, South San Francisco, Thousand Oaks) / Colorado (Boulder, Longmont) / Kentucky (Louisville) / Massachusetts (Cambridge) / Puerto Rico (Juncos) / Rhode Island (West Greenwich) / Washington (Bothell, Seattle) / Washington, D.C.

Outside the United States

Australia / Austria / Barbados / Belgium / Canada / China / Czech Republic / Denmark / Estonia / Finland / France / Germany / Hong Kong / Hungary / Ireland / Italy / Japan / Latvia / Lithuania / Luxembourg / Mexico / Netherlands / Norway / Poland / Portugal / Slovakia / Slovenia / Spain / Sweden / Switzerland / United Arab Emirates / United Kingdom

Commitment to Science

Being science-based is one of the Amgen core values and the essence of our culture. The company was founded to realize the potential of biotechnology, and our success always depends upon our ability to drive scientific innovation. Understanding human biology and the role that genes, and the proteins expressed by them, play in the disease process is the cornerstone of our method. Changing the practice of medicine for the benefit of patients is our ultimate objective.

QUICK FACTS

Headquarters

Thousand Oaks, California

Full-Time Staff

19,400

Stock Listing

NASDAQ: AMGN

Chairman and CEO

Kevin W. Sharer

2005 Financial Highlights

Total revenue: \$12.4 billion

Product sales: \$12.0 billion

R&D investment: \$2.3 billion

Address/Phone

One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Main: (805) 447-1000

Media: (805) 447-4587

Investors: (805) 447-1060

OUR MISSION

To serve patients

CEO STAFF

Kevin W. Sharer
Chairman of the Board,
Chief Executive Officer, and President

Dennis M. Fenton
Executive Vice President,
Operations

Tom Flanagan
Senior Vice President and
Chief Information Officer

Brian M. McNamee
Senior Vice President,
Human Resources

George J. Morrow
Executive Vice President,
Global Commercial Operations

Richard D. Nanula
Executive Vice President
and Chief Financial Officer

Roger M. Perlmutter
Executive Vice President,
Research and Development

David J. Scott
Senior Vice President,
General Counsel, and Secretary

INVESTOR INFORMATION

This fact sheet is a summary of more detailed disclosure that can be found in Amgen's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Amgen's most recent Forms 10-K, 10-Q, and 8-K and on www.amgen.com/investors. The information in this fact sheet is given as of the date below, and Amgen does not undertake any obligation to update any information in this document.

Our commitment to science goes beyond the lab, clinic and manufacturing plant. We rely on the scientific method to drive continuous improvement in every aspect of our business. We value open inquiry and logical and rational processes; we seek to ask the right questions, collect and analyze the relevant data and make informed decisions.

An Interdisciplinary Approach to R&D

For more than 25 years, Amgen has been a leading innovator in the identification, isolation, production and use of human proteins as therapeutic agents. Today, Amgen scientists work at the cutting edge between the traditional disciplines of chemistry and cellular and molecular biology in an effort to discover and develop the medical breakthroughs of tomorrow. We focus on pioneering treatments for serious illness. As part of that commitment, our R&D organization has cultivated expertise in multiple treatment modalities—large-molecule proteins, small molecules and antibodies—allowing us to choose the best target for attacking disease and to use the modality most likely to affect that target.

Amgen has research programs in inflammation, metabolic disorders and osteoporosis, neuroscience, oncology and hematology. Our research facilities are located in South San Francisco and Thousand Oaks, California; Cambridge, Massachusetts; Seattle, Washington; Burnaby, British Columbia, Canada; and Regensburg, Germany.

A Pioneer in Biotechnology Manufacturing

Assuring that Amgen medicines rapidly, reliably and safely reach "every patient, every time" is the charge of Amgen's manufacturing, process development, quality and distribution teams. From the beginning, the company's contributions to the field of biotechnological production of human therapeutics have been driven by a strong commitment to meet the needs of patients.

Manufacturing therapies based on proteins found in the human body is a complex and highly specialized activity. From process development and clinical manufacturing to full-scale therapeutic protein production, Amgen has built one of the industry's largest and most reliable operations, and the company continues to expand its capabilities.

Amgen operates manufacturing facilities in California, Colorado, Rhode Island, Washington, and Puerto Rico. In early 2006, Amgen announced its intention to invest more than \$1 billion to build a new manufacturing facility in Cork, Ireland. The Cork facility, which the company expects to begin operating in 2009, will help Amgen ensure supplies of medicines for patients in Europe and other parts of the world.

Advancing Science through Strategic Partnerships

With more than 100 active collaborations, Amgen is well-suited to be a partner of choice in the human therapeutics business. With the capabilities and financial strength of a large company, Amgen can offer partners the resources to support a potential new medicine as it advances from lab to clinic to marketplace. At the same time, Amgen retains the agility and decisiveness of a smaller biotech, with an unwavering commitment to science and patients.

AMGEN HISTORY

1980

- AMGen (Applied Molecular Genetics Inc.) established on April 8
- George B. Rathmann named CEO

1983

- Company changes name to Amgen
- A research team lead by Fu-Kuen Lin clones the gene for human erythropoietin (EPO) and subsequently produces recombinant EPO, later patented and named EPOGEN® (Epoetin alfa)
- Initial public offering raises nearly \$40 million

1985

- A research team led by Larry Souza clones the gene for granulocyte colony-stimulating factor (G-CSF) and produces recombinant G-CSF, later patented and named NEUPOGEN® (Filgrastim)

1987

- Amgen receives first patent on DNA used in producing Epoetin alfa

1988

- Gordon M. Binder named CEO

1989

- Immunex discovers and files a patent application on a new tumor necrosis factor receptor that will be developed to become Enbrel® (etanercept)
- Amgen receives first patent for recombinant G-CSF (NEUPOGEN®)
- The U.S. Food and Drug Administration (FDA) approves EPOGEN® for treatment of anemia in adult patients with chronic renal failure who are on dialysis
- Amgen opens first offices in Europe

1991

- FDA approves NEUPOGEN® to decrease the incidence of infection associated with chemotherapy-induced neutropenia in patients with non-myeloid cancers
- Amgen establishes the Amgen Foundation for charitable giving
- Federal Appeals Court rules in favor of Amgen in EPO patent dispute with Genetic Institute
- Amgen opens offices in Australia and Canada

1993

- Amgen opens Amgen K.K., the company's subsidiary in Japan

1994

- Amgen receives U.S. Department of Commerce National Medal of Technology

1998

- FDA approves Enbrel® (etanercept) to treat patients with rheumatoid arthritis

Principal Products (U.S. Indications)

Aranesp® (darbepoetin alfa) is prescribed for the treatment of anemia associated with chronic kidney disease and chemotherapy. *Aranesp® is contraindicated in patients with uncontrolled hypertension.*

Enbrel® (etanercept) is prescribed for the treatment of moderately-to-severely-active rheumatoid arthritis, polyarticular-course juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (arthritis of the spine), and moderate to severe plaque psoriasis in adults. *Patients on Enbrel® have reported serious adverse events, some of them fatal, including infections, neurologic and hematologic disorders, and lymphoma. The most common adverse events are injection site reactions.*

EPOGEN® (Epoetin alfa) is prescribed for the treatment of anemia in patients with chronic kidney disease who are on dialysis. *EPOGEN® is contraindicated in patients with uncontrolled hypertension.*

Kepivance® (palifermin) is prescribed to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients with hematologic (blood) cancers who are undergoing high-dose chemotherapy, with or without radiation, followed by bone marrow transplant. The safety and efficacy of Kepivance® have not been established in patients with non-hematologic malignancies. *In clinical trials, the most common serious adverse reaction attributed to Kepivance® as in rash, reported in less than 1 percent of patients.*

Neulasta® (pegfilgrastim) or **NEUPOGEN®** (Filgrastim) is prescribed to reduce the risk of infection (initially marked by fever) in certain cancer patients who are receiving chemotherapy that could decrease their number of infection-fighting white blood cells. Neulasta® is a longer-acting form of NEUPOGEN® that requires only one injection per chemotherapy cycle—a meaningful benefit for patients. *Rare events of adult respiratory distress syndrome, splenic rupture, and sickle cell crises have been reported in postmarketing experience in patients receiving NEUPOGEN® or Neulasta®.*

Sensipar® (cinacalcet HCl) is an oral therapy prescribed to treat hyperparathyroidism caused by chronic kidney disease; it is approved for use in patients who are receiving dialysis. It is also indicated to treat elevated calcium levels in patients with malignant tumors of the parathyroid gland. *Sensipar® lowers serum calcium. Significant reductions in calcium may lower the threshold for seizures.*

Vectibix™ is indicated for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. The effectiveness of Vectibix™ for the treatment of EGFR-expressing metastatic colorectal carcinoma is based on progression-free survival. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Vectibix™. *Serious adverse events, some fatal, have been seen in clinical trials of Vectibix™, including dermatologic toxicities (reported in 89% of patients, with severe dermatologic toxicities in 12% of patients) and severe infusion reactions (reported in 1% of patients).*

For additional product information, see www.amgen.com.

1999

- FDA approves ENBREL to treat moderately-to-severely-active polyarticular-course juvenile rheumatoid arthritis

2000

- Kevin W. Sharer named CEO

2001

- Regulators in the U.S. and Europe approve Aranesp® (darbepoetin alfa) to treat anemia associated with chronic renal failure

2002

- Regulators in the U.S. and Europe approve Neulasta® (pegfilgrastim) to decrease the incidence of infection in patients with non-myeloid cancers who are receiving chemotherapy
- Regulators in the U.S. and Europe approve Aranesp® for the treatment of chemotherapy-induced anemia in patients with non-myeloid malignancies
- Amgen completes Immunex acquisition
- FDA approves ENBREL to treat the signs and symptoms of active arthritis in patients with psoriatic arthritis

2003

- FDA approves ENBREL for the treatment of ankylosing spondylitis and other expanded indications

2004

- FDA approves Sensipar® (cinacalcet HCl) for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis
- FDA approves ENBREL for the treatment of chronic moderate to severe plaque psoriasis in adults
- Amgen completes acquisition of Tularik Inc.
- FDA approves Kevivance® (palifermin) to decrease the incidence and duration of severe oral mucositis in patients with hematologic cancers who are undergoing high-dose chemotherapy and bone marrow transplant

2005

- FDA grants licensure to two new Amgen manufacturing facilities in West Greenwich, RI, and Juncos, PR.

2006

- Amgen completes acquisition of Abgenix, Inc.
- FDA approves Vectibix™ (panitumumab) for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens

Community Involvement

In the communities in which Amgen staff live and work, the company commits millions of dollars in charitable donations, and staff members devote thousands of hours of personal time to programs and services that can make meaningful differences in people's lives.

The company sustains many programs, including the Amgen Staff Volunteer Program, sponsorship of community events, and the Amgen Awards for Science Teaching Excellence.

One of the most important vehicles for Amgen's corporate philanthropy is the **Amgen Foundation**. Since its founding in 1991, the Amgen Foundation has contributed more than \$70 million to regional and national nonprofit groups that advance science education, improve quality of care and access for patients, and support vital community resources. The Foundation also matches Amgen staff member donations to eligible organizations. Since the inception of the Matching Gift Program in 1993, the Foundation has matched \$10.5 million in staff donations, resulting in more than \$21 million in support of worthy organizations across the United States and Puerto Rico.

Recent Recognition

In *Barron's* investor survey of the most respected global companies, published September 2006, Amgen ranked 10th and was the highest-ranked biotechnology company on the list.

Amgen placed 33rd in *Business Week's* Global 1200 in December 2005.

Amgen ranked 51st in the *Financial Times* "Europe's Global 500" in 2005.

Amgen was named *Forbes's* "Company of the Year" for 2004.

On *Fortune's* 2006 list of "America's Most Admired Companies," Amgen ranked third in its industry. In 2006, Amgen appeared for the seventh time on *Fortune's* "100 Best Companies to Work For in America" list.

Amgen was named 2006 "Company of the Year" by *Pharmaceutical Executive*.

In 2006, for the second year in a row, Amgen's pipeline was named "Best Biotechnology Pipeline" by *R&D Directions* and *Med Ad News*.

Amgen ranked second in *Science's* 2005 survey of the best biotechnology and pharmaceutical employers, out of 459 companies evaluated.

Amgen was ranked first among large companies by *The Scientist* on its 2006 "Best Places to Work in Industry" survey.

Industry Affiliations

Amgen actively participates in industry organizations such as the Biotechnology Industry Organization, the Healthcare Leadership Council, and Pharmaceutical Research and Manufacturers of America.

